Galaxy agreement provides access to more than 3.5 million patients Through a network of more than 400,000 suppliers
LAGUNA HILLS, CA., August 31, 2022 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has signed an agreement with Galaxy Health Network to cover the new Company DCISionRTa test for ductal carcinoma in situ (DCIS), also known as stage zero breast cancer. Under the agreement, Galaxy’s more than 3.5 million members and more than 400,000 vendors will now have access to DCISionRT.
“Galaxy joins the growing list of health insurance providers that cover DCISionRT, enabling even more physicians and patients to access DCISionRT whether or not they are on the network,” said Dan Forche, President and CEO of PreludeDx. “DCISionRT is the only test that predicts personalized recurrence risk and benefit of radiation therapy (RT) for patients with DCIS. Our personalized results provide physicians and patients with critical information to optimize DCIS treatment plans and avoid over- or under-treatment. We are committed to ensuring all patients have access to the benefits of the DCISionRT test.”
About Galaxy Health Network
Galaxy Health Network, headquartered in Arlington, Texas, is a national managed care provider with more than 3.5 million lives covered. Galaxy Health Network’s Preferred Provider organization includes a network of more than 400,000 contract physicians, 2,700 hospitals, and 47,000 ancillary providers. For more information, visit http://ghn-mci.com
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts the benefit of radiation therapy. Patients with DCIS have cancer cells lining the milk ducts of the breast, but they have not spread to surrounding breast tissue. In the United States, more than 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from University of California San Francisco, and building on research that began with funding from the National Cancer Institute, helps doctors better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman’s individual tumor biology as well as other disease risk factors and provide personalized recurrence risk. The test provides a decision scoreMT which identifies a woman’s risk as low or high. Unlike other risk assessment tools, the DCISionRT assay combines protein expression from seven biomarkers and four clinicopathologic factors, using a nonlinear algorithm to account for multiple interactions between individual factors to better interpret complex biological information. DCISionRT’s smart reports provide a woman’s risk of recurrence after breast-conserving surgery alone and with the addition of radiation therapy. In turn, this new information can help patients and their doctors make more informed treatment decisions.
PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx is focused on developing precision breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden on the healthcare system. Before making a treatment decision, know your riskMT. PreludeDx is a portfolio company of Fjord Ventures.
For more information on how PreludeDx is making a difference for patients, please visit the company’s website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.
PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in United States and foreign countries.